Abstract
Objectives
To estimate an optimal follow-up (FU) interval for von Hippel-Lindau (VHL) patients with renal masses (RMs) by determining tumour growth rates from growth curves.
Methods
Thirty lesions (47.6 %) were classified as solid tumours (STs) and 33 (52.4 %) as complex cysts (CCs). Variations in lesion volume over time were analyzed. For 53 lesions, we calculated the growth rate during the period when the volume of the lesion changed most rapidly, and called this the fast growth rate (FGR).
Results
The STs initially grew fast, followed by a period of slower growth. The CCs varied in volume over time, associated with variable amounts of their fluid component. The FGR correlated better with the latest volume for STs (r = 0.905) than for CCs (r = 0.780). An optimal FU interval between 3 and 12 months was derived by combining the FGR calculated from the curve with the latest volume measured.
Conclusions
Analyzing growth curves and related kinetic parameters for RMs in VHL patients could be useful with a view to optimizing the subsequent FU interval and improving the active surveillance program.
Key Points
• Measuring volume changes over time enables tumour growth curves to be charted.
• Renal solid tumours increase in volume with a typical sigmoidal curve.
• Complex cysts may increase and decrease in volume spontaneously over time.
• The fast growth rate of solid tumours correlates with their latest volume.
• The fast growth rate can orient the scheduling of subsequent follow-ups.
Similar content being viewed by others
Abbreviations
- CCs:
-
Complex cysts
- DT:
-
Doubling time
- FGR:
-
Fast growth rate
- FU:
-
Follow-up
- GR:
-
Growth rate
- MRI:
-
Magnetic resonance imaging
- RCC:
-
Renal cell carcinoma
- RMs:
-
Renal masses
- STs:
-
Solid tumours
- VHL:
-
Von Hippel-Lindau
References
Lonser RR, Glenn GM, Walther M et al (2003) Von hippel-lindau disease. Lancet 361:2059–2067
Verine J, Pluvinage A, Bousquet G et al (2010) Hereditary renal cancer syndromes: An update of a systematic review. Eur Urol 58:701–710
Kim JJ, Rini BI, Hansel DE (2010) Von hippel lindau syndrome. Adv Exp Med Biol 685:228–249
Latif F, Tory K, Gnarra J et al (1993) Identification of the von hippel-lindau disease tumor suppressor gene. Science 260:1317–1320
Meister M, Choyke P, Anderson C, Patel U (2009) Radiological evaluation, management, and surveillance of renal masses in von hippel-lindau disease. Clin Radiol 64:589–600
Choyke PL, Glenn GM, Walther MM et al (1992) The natural history of renal lesions in von hippel-lindau disease: A serial CT study in 28 patients. AJR Am J Roentgenol 159:1229–1234
Walther MM, Choyke PL, Glenn G et al (1999) Renal cancer in families with hereditary renal cancer: Prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol 161:1475–1479
Duffey BG, Choyke PL, Glenn G et al (2004) The relationship between renal tumor size and metastases in patients with von hippel-lindau disease. J Urol 172:63–65
Ploussard G, Droupy S, Ferlicot S et al (2007) Local recurrence after nephron-sparing surgery in von hippel-lindau disease. Urology 70:435–439
Boss A, Clasen S, Kuczyk M, Schick F, Pereira PL (2007) Image-guided radiofrequency ablation of renal cell carcinoma. Eur Radiol 17:725–733
Shingleton WB, Sewell PE Jr (2002) Percutaneous renal cryoablation of renal tumors in patients with von hippel-lindau disease. J Urol 167:1268–1270
Afenya EK, Calderon CP (2000) Diverse ideas on the growth kinetics of disseminated cancer cells. Bull Math Biol 62:527–542
Bajzer Z (1999) Gompertzian growth as a self-similar and allometric process. Growth Dev Aging 63:3–11
Domingues JS (2012) Gompertz model: Resolution and analysis for tumors. J Math Model Appl 1:70–77
Collins VP, Loeffler RK, Tivey H (1956) Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 76:988
Jilg CA, Neumann HP, Glasker S et al (2012) Growth kinetics in von hippel-lindau-associated renal cell carcinoma. Urol Int 88:71–78
Zhang J, Pan JH, Dong BJ, Xue W, Liu DM, Huang YR (2012) Active surveillance of renal masses in von hippel-lindau disease: Growth rates and clinical outcome over a median follow-up period of 56 months. Fam Cancer 11:209–214
Bosniak MA (1997) The use of the bosniak classification system for renal cysts and cystic tumors. J Urol 157:1852–1853
Nikken JJ, Krestin GP (2007) MRI of the kidney-state of the art. Eur Radiol 17:2780–2793
Pedrosa I, Chou MT, Ngo L et al (2008) MR classification of renal masses with pathologic correlation. Eur Radiol 18:365–375
Crispen PL, Wong YN, Greenberg RE, Chen DY, Uzzo RG (2008) Predicting growth of solid renal masses under active surveillance. Urol Oncol 26:555–559
Choi SJ, Kim HS, Ahn SJ, Park Y, Choi HY (2012) Differentiating radiological features of rapid- and slow-growing renal cell carcinoma using multidetector computed tomography. J Comput Assist Tomogr 36:313–318
Kurup AN, Thompson RH, Leibovich BC et al (2012) Renal oncocytoma growth rates before intervention. BJU Int 110:1444–1448
Li XS, Yao L, Gong K et al (2012) Growth pattern of renal cell carcinoma (RCC) in patients with delayed surgical intervention. J Cancer Res Clin Oncol 138:269–274
Kassouf W, Aprikian AG, Laplante M, Tanguay S (2004) Natural history of renal masses followed expectantly. J Urol 171:111–113
Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA (2004) The natural history of incidentally detected small renal masses. Cancer 100:738–745
Lamb GW, Bromwich EJ, Vasey P, Aitchison M (2004) Management of renal masses in patients medically unsuitable for nephrectomy–natural history, complications, and outcome. Urology 64:909–913
Lee JY, Kim CK, Choi D, Park BK (2008) Volume doubling time and growth rate of renal cell carcinoma determined by helical CT: A single-institution experience. Eur Radiol 18:731–737
Acknowledgments
The authors would like to thank Andrea Azzalini for help in preparing the illustrations. The scientific guarantor of this publication is Gisella Gennaro. The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article. The authors state that this work has not received any funding. One of the authors has significant statistical expertise. Institutional Review Board approval was obtained. Written informed consent was not required for this study because it retrospectively evaluated images already acquired for the standard patient FU, with no effect on the patients themselves. The study subjects have never been previously reported. Methodology: retrospective, observational, performed at one institution.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pomerri, F., Opocher, G., Bosco, C.D. et al. Optimal follow-up intervals in active surveillance of renal masses in patients with von Hippel-Lindau disease. Eur Radiol 25, 2025–2032 (2015). https://doi.org/10.1007/s00330-015-3591-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-015-3591-9